Persistence of elevated deamidated gliadin peptide antibodies on a gluten-free diet indicates nonresponsive coeliac disease. Spatola, BN., Kaukinen, K., Collin, P., Mäki, M., Kagnoff, MF., Daugherty, PS. Aliment. Pharmacol. Ther. 39(4): 407-17. (6th February 2014).


Characterization of Antibody Specificities Associated With Preeclampsia. Elliott, SE., Parchim, NF., Liu, C., Xia, Y., Kellems, RE., Soffici, AR., Daugherty, PS. Hypertension [Epub ahead of print]. (20th January 2014)


Antibody biomarker discovery through in vitro directed evolution of consensus recognition epitopes. Ballew, JT., Murray, JA., Collin, P., Mäki, M., Kagnoff, MF., Kaukinen, K., Daugherty, PS. Proc. Natl. Acad. Sci. U.S.A. 110(48): 19330-5. (26th November 2013).


A novel quantitative kinase assay using bacterial surface display and flow cytometry. Henriques, ST., Thorstholm, L., Huang, YH., Getz, JA., Daugherty, PS., Craik, DJ. PLoS ONE 8(11): e80474. (15th November 2013)


Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index. Desnoyers, LR., et al. Sci Transl Med 5(207): 207ra144. (16th October 2013)

Design of a cyclotide antagonist of neuropilin-1 and -2 that potently inhibits endothelial cell migration. Getz, JA., Cheneval, O., Craik, DJ., Daugherty, PS. ACS Chem. Biol. 8(6): 1147-54. (21st June 2013)


Antibody repertoire profiling using bacterial display identifies reactivity signatures of celiac disease. Spatola, BN., Murray, JA., Kagnoff, M., Kaukinen, K., Daugherty, PS. Anal. Chem. 85(2): 1215-22. (15th January 2013)


Site-specific targeting of antibody activity in vivo mediated by disease-associated proteases. Erster, O., et al. J Control Release 161(3): 804-12. (10th August 2012)


Protease-resistant peptide ligands from a knottin scaffold library. Getz, JA., Rice, JJ., Daugherty, PS. ACS Chem. Biol. 6(8): 837-44. (19th August 2011)

Bacterial display enables efficient and quantitative peptide affinity maturation. Kenrick, SA., Daugherty, PS. Protein Eng. Des. Sel. 23(1): 9-17. (31st December 2009)


Quantitative specificity-based display library screening identifies determinants of antibody-epitope binding specificity. Hall, SS., Daugherty, PS. Protein Sci. 18(9): 1926-34. (31st August 2009)

 Leading Technology


Pinpoint disease specific biomarkers


ADEPT directly identifies antibody biomarkers in patient biospecimens that are unique to the disease state, and optimal peptide reagents for their accurate detection.

Publications by Serimmune Scientists

Identify novel drug Targets


Disease specific antibodies are increasingly found to play a role in driving disease. Thus, our peptides that selectively and potently block these antibodies are being pursued as therapeutic agents for autoimmune indications.

Move beyond autoantigens


Unlike existing technologies that attempt to match antibody biomarkers to human proteome antigens (autoantigens), ADEPT matches disease specific antibodies to their preferred antigens that are often from the environment.

Evolve Dx performance


In vitro molecular evolution using our patented peptide library technology yields peptide reagents that precisely recognize disease specific antibodies.